StacyE.CroteauMD

Hemophilia & Bleeding Disorder

Director Hemophilia/VWD Program, Boston Children's Hospital Assistant Professor of Pediatrics, Harvard Medical School

Dr. Croteau is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
300 Longwood Ave
.
Boston, MA 02115
Phone+1 617-355-8246

Fax+1 617-730-0641

Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2011 - 2014
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2007 - 2011
The Warren Alpert Medical School of Brown UniversityClass of 2007

A Gene Transfer Study for Hemophilia A Start of enrollment: 2017 Jan 26
Completed
Phase 1, Phase 2
Roles: Contact

PubMed

90 citations
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.
Lindsey A. George, Paul E Monahan, M Elaine Eyster, Spencer K. Sullivan, Margaret V Ragni
The New England Journal of Medicine. 2021-11-18
20 citations
The Impact of Extended Half‐Life Factor Concentrates on Prophylaxis for Severe Hemophilia in The United States
Lynn M. Malec, Dunlei Cheng, Char Witmer, Julie Jaffray, Peter A. Kouides
American Journal of Hematology. 2020-08-01
106 citations
Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly
Stacy E. Croteau, Harry P.W. Kozakewich, Antonio R. Perez-Atayde, Steven J. Fishman, Ahmad I. Alomari
The Journal of Pediatrics. 2014-02-01

Lectures

Advances in Hemophilia A: Expert Guidance and Practical Case Discussions
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Risk Factors for Hospital-Acquired Venous Thromboembolism in Children: Findings from the Children’s Hospital-Acquired Thrombosis (CHAT) Registry
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Thrombotic Events with NovoSeven® RT in Approved Indications Are Rare (0.2%) and Associated with Older Age (>= 65 y), Cardiovascular Disease, and Concomitant Use of aPCCs
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Gene Therapy Can Transform Life for People with Hemophilia. But Some Patients Don’t Want ItJanuary 29th, 2023
BioMarin: Depressed Price Due to CRL, Major Catalysts AheadJune 1st, 2021
Gene Therapy for Hemophilia: Progress and SetbacksOctober 20th, 2020
Join now to see all